Drug
Lenvatinib
Data on this page refer exclusively to patients treated with
Lenvatinib combined with SBRT, without concurrent use of
drugs from other classes.
Combination therapy data and pooled group-level evidence are available on the
Multi-target TKI group page.
Drug Profile
| Therapeutic Class | Targeted Therapy |
| Drug Class | Tyrosine Kinase Inhibitors (TKIs) |
| Group | Multi-target TKI |
| Mechanism of Action | VEGFR/FGFR/PDGFR inhibitor |
| Half-life | 28 h |
